It can be expected that IgA-based BsAbs, in conjunction with the frontline microbiota target therapeutics i.e., probiotics and prebiotics, would underpin a paradigm shift in the treatment of immunological disorders and communicable diseases. Here, CD79A is linked to infectious disease.